NASH 11/2023 Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model 7th Obesity and NASH Drug Development Summit Graviton Love0
NASHPUBLICATIONS 11/2023 Artificial Intelligence Based Digital Pathology Reveals Fatty Acid Synthase (FASN) Inhibitor Alone or in Combination with Semaglutide Improves Fibrosis in Diet-Induced Obese Mice with Biopsy-Confirmed NASH and Fibrosis AASLD The Liver Meeting Graviton Love0
NASHPUBLICATIONS 11/2023 Interim Analysis of FASCINATE-2 A Phase 2b Randomized, Placebo Controlled Trial Demonstrated Denifanstat Reduces Circulating Saturated Diacylglycerols and Triacylglycerols, Markers of Lipotoxicity AASLD The Liver Meeting Graviton Love0
Oncology 04/2023 Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma Clinical Cancer Research Graviton Love0
Oncology 02/2023 Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development HCC-TAG Graviton Love0
NASH 01/2023 Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies NASH-TAG Graviton Love0
NASH 01/2023 Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients NASH-TAG Graviton Love0
PRESS RELEASES 11/2022 Sagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe Non-alcoholic Steatohepatitis (NASH) Patients Denifanstat Showed Statistically Significant Improvements Across Key Disease Markers in FASCINATE-2 Study After 26 Weeks of Treatment Highlights to be Included in Oral Presentation Session at The Liver Meeting on… Graviton Love4
NASH 11/2022 Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH AASLD The Liver Meeting Graviton Love0
NASH 11/2022 A baseline metabolomic signature predicts liver fat (MRI-PDFF) response for denifanstat, a first-in-class, fatty acid synthase (FASN) inhibitor: analysis in FASCINATE-1 and FASCINATE-2 clinical studies AASLD The Liver Meeting Graviton Love0